Ifosfamide and Doxorubicin Combination Chemotherapy for Recurrent Nasopharyngeal Carcinoma Patients

Dede, Didem Sener; Aksoy, Sercan; Cengiz, Mustafa; Gullu, Ibrahim; Altundag, Kadri

추천

검색

자료유형: 학술저널

저자정보: Dede, Didem Sener (Department of Medical Oncology, Hacettepe University Faculty of Medicine) Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Faculty of Medicine) Cengiz, Mustafa (Department of Radiation Oncology, Hacettepe University Faculty of Medicine) Gullu, Ibrahim (Department of Medical Oncology, Hacettepe University Faculty of Medicine) Altundag, Kadri (Department of Medical Oncology, Hacettepe University Faculty of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제5호

발행연도: 2012.1

수록면: 2,225 - 2,228 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: We assessed the efficacy and toxicity of ifosfamide and doxorubicin combination chemotherapy (CT) regimen retrospectively in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. Methods: A total of thirty patients who had received cisplatin based chemotherapy/chemoradiotherapy as a primary treatment received ifosfamide 2500 $mg/m^2$ days 1-3, mesna 2500 $mg/m^2$ days 1-3, doxorubicin 60 mg/m2 day 1 (IMA), repeated every 21 days. Eligible patients had ECOG PS< 2, measurable recurrent or metastatic disease, with adequate renal, hepatic and hematologic functions. Results: Median age was 47 (min-max; 17-60). Twenty six (86.7 %) were male. Median cycles of chemotherapy for each patient were 2 (range:1-6). Twenty patients were evaluable for toxicity and response. No patient achieved complete response, with nine partial responses for a response rate of 30.0% in evaluable patients. Stable disease, and disease progression were observed in five (16.7%) and six (20.0%) patients, respectively. Clinical benefit was 46.7%. Median time to progression was 4.0 months. Six patients had neutropenic fever after IMA regimen and there were one treatment-related death due to tumor lysis syndrome in first cycle of the CT. No cardiotoxicity was observed after CT and treatments were generally well tolerated. Conclusion: Ifosfomide and doxorubicin combination is an effective regimen for patients with recurrent and metastatic NPC. For NPC patients demonstrating failure of cisplatin based regimens, this CT combination may be considered as salvage therapy.

#Nasopharyngeal carcinoma #ifosfamide #doxorubicin #chemotherapy #recurrent

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Dede, Didem Sener

소속기관 Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University, Ataturk Research a